This inventor holds 2 USPTO granted patents. Top assignees: Behringwerke Aktiengesellschaft, Sanofi-Arentideutschland Gmbh, The General Hospital Corporation. Active years: 1997-2007.
Company Filing History:
1 out of 340 
1 out of 1 
1 out of 3,070 
Years Active: 1997-2007
Title: Patricia Oquendo: Innovator in Biopharmaceuticals
Introduction
Patricia Oquendo is a distinguished inventor based in Marburg, Germany. She has made significant contributions to the field of biopharmaceuticals, particularly through her innovative patents. With a total of 2 patents, her work focuses on the development of advanced therapeutic proteins.
Latest Patents
One of her latest patents is titled "Immunoglobulin fusion proteins, their production and use." This invention relates to genetically engineered soluble fusion proteins composed of human proteins not belonging to the immunoglobulin family, or parts thereof, along with various portions of the constant region of immunoglobulin molecules. Remarkably, the functional properties of the two fusion partners are retained in the fusion protein. Another notable patent is "Cell-free receptor binding assays, the production and use thereof." This invention allows for the investigation of the binding behavior of receptor proteins in the cell membrane toward natural or artificial ligands. It involves linking the particular receptor to a suitable carrier molecule, preferably the heavy chain of an immunoglobulin, while retaining its biological properties.
Career Highlights
Throughout her career, Patricia has worked with prominent organizations, including Sanofi-Aventis Deutschland GmbH and The General Hospital Corporation. Her experience in these companies has allowed her to refine her expertise in biopharmaceutical research and development.
Collaborations
Patricia has collaborated with notable colleagues such as Leander Lauffer and Gerd Zettlmeissl. These partnerships have contributed to her innovative work and the advancement of her research.
Conclusion
Patricia Oquendo is a remarkable inventor whose contributions to biopharmaceuticals have the potential to impact the medical field significantly. Her innovative patents and collaborations highlight her dedication to advancing therapeutic technologies.